Literature DB >> 24925031

Pancreatic cancer stem cells: association with cell surface markers, prognosis, resistance, metastasis and treatment.

Timothy L Fitzgerald1, James A McCubrey2.   

Abstract

In this review, we will discuss the recent advances in understanding the pancreatic cancer stem cells. Identification and characterization of pancreatic cancer stem cells may aid our ability to improve diagnosis and treatment of pancreatic cancer. Novel approaches are necessary for the earlier diagnosis of pancreatic cancer as well as improved treatment to prevent distal metastasis. Key markers for the identification of pancreatic cancer stem cells include CD133, ALDH, side population cells and the triplet combination CD44+ CD24+ESA+. The roles of these proteins as markers for stemness in pancreatic cancer as well as recent studies with the c-Met proto-oncogene will be discussed. The ability of these markers to predict survival of pancreatic cancer patients is being examined clinically. Stemness and resistance to chemotherapy and radiotherapy may be linked. Expression of some of these markers may be associated with distant metastasis. Treatment of pancreatic cancer patients by targeting the pancreatic cancer stem cells holds promise.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  CD44; Metastases; Pancreatic cancer stem cell; Stemness; c-Met; cabozantinib

Mesh：

Substances：

Year:  2014        PMID： 24925031     DOI： 10.1016/j.jbior.2014.05.001

Source DB:  PubMed          Journal:  Adv Biol Regul        ISSN： 2212-4926


  34 in total

1.  Relationship between CD44high/CD133high/CD117high cancer stem cells phenotype and Cetuximab and Paclitaxel treatment response in head and neck cancer cell lines.

Authors:  Ana Livia Silva Galbiatti-Dias; Glaucia Maria Mendonça Fernandes; Marcia Maria Urbanin Castanhole-Nunes; Luiza Fernandes Hidalgo; Carlos Henrique Viesi Nascimento Filho; Rosa Sayoko Kawasaki-Oyama; Leticia Antunes Muniz Ferreira; Patricia Matos Biselli-Chicote; Érika Cristina Pavarino; Eny Maria Goloni-Bertollo
Journal:  Am J Cancer Res       Date:  2018-08-01       Impact factor: 6.166

Review 2.  Lipid rafts as signaling hubs in cancer cell survival/death and invasion: implications in tumor progression and therapy: Thematic Review Series: Biology of Lipid Rafts.

Authors:  Faustino Mollinedo; Consuelo Gajate
Journal:  J Lipid Res       Date:  2020-11-07       Impact factor: 5.922

Review 3.  Lipid rafts as signaling hubs in cancer cell survival/death and invasion: implications in tumor progression and therapy.

Authors:  Faustino Mollinedo; Consuelo Gajate
Journal:  J Lipid Res       Date:  2020-01-27       Impact factor: 5.922

4.  Cancer Stem Cell Markers, CD44 and ALDH1, for Assessment of Cancer Risk in OPMDs and Lymph Node Metastasis in Oral Squamous Cell Carcinoma.

Authors:  Snehal Navnath Dhumal; Sheetal Korde Choudhari; Sangeeta Patankar; Shrikrishna S Ghule; Yogesh B Jadhav; Sneha Masne
Journal:  Head Neck Pathol       Date:  2021-10-16

Review 5.  Pancreatic cancer stem cell markers and exosomes - the incentive push.

Authors:  Sarah Heiler; Zhe Wang; Margot Zöller
Journal:  World J Gastroenterol       Date:  2016-07-14       Impact factor: 5.742

6.  Myrtucommulone-A treatment decreases pluripotency- and multipotency-associated marker expression in bladder cancer cell line HTB-9.

Authors:  Banu Iskender; Kenan Izgi; Halit Karaca; Halit Canatan
Journal:  J Nat Med       Date:  2015-06-09       Impact factor: 2.343

Review 7.  Cancer stem cells as targets for immunotherapy.

Authors:  Amy S Codd; Takayuki Kanaseki; Toshihiko Torigo; Zsuzsanna Tabi
Journal:  Immunology       Date:  2017-12-18       Impact factor: 7.397

Review 8.  Pancreatic Cancer and Therapy: Role and Regulation of Cancer Stem Cells.

Authors:  Susmita Barman; Iram Fatima; Amar B Singh; Punita Dhawan
Journal:  Int J Mol Sci       Date:  2021-04-30       Impact factor: 5.923

9.  Wild type and gain of function mutant TP53 can regulate the sensitivity of pancreatic cancer cells to chemotherapeutic drugs, EGFR/Ras/Raf/MEK, and PI3K/mTORC1/GSK-3 pathway inhibitors, nutraceuticals and alter metabolic properties.

Authors:  James A McCubrey; Akshaya K Meher; Shaw M Akula; Stephen L Abrams; Linda S Steelman; Michelle M LaHair; Richard A Franklin; Alberto M Martelli; Stefano Ratti; Lucio Cocco; Fulvio Barbaro; Przemysław Duda; Agnieszka Gizak
Journal:  Aging (Albany NY)       Date:  2022-04-27       Impact factor: 5.682

10.  mTOR Inhibition Ablates Cisplatin-Resistant Salivary Gland Cancer Stem Cells.

Authors:  T Nakano; K A Warner; A E Oklejas; Z Zhang; C Rodriguez-Ramirez; A G Shuman; J E Nör
Journal:  J Dent Res       Date:  2020-10-17       Impact factor: 8.924
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.